Microfluidics, a wholly owned subsidiary of Microfluidics
International Corporation (OTCBB: MFLU), recently was invited to participate
in POWREX Corporation's annual New Pharmaceutical Technology and Engineering
Conference, which is among Japan's premier annual pharmaceutical events.
Microfluidics Chief Technology Officer Thomai "Mimi" Panagiotou,
Ph.D., delivered a presentation on production of nanomaterials for pharmaceutical
applications using high shear fluid processors. Primarily Dr. Panagiotou featured
innovative bottom-up Microfluidics Reaction Technology (MRT) for continuous
crystallization, chemical reactions and process intensification.
Held on July 22-23 at POWREX's corporate headquarters in Tokyo, Japan,
the symposium was attended by more than 350 senior pharmaceutical executives.
Dr. Panagiotou joined fellow keynote speakers from Merck and Co., GlaxoSmithKline,
Takeda Pharmaceutical Company, Boehringer Ingelheim and Novartis along with
other leaders from industry, academia and international government organizations.
Topics ranged from new quality paradigms in pharmaceutical manufacturing to
advanced drug delivery methodologies. The thought-provoking event featured engaging
and thoughtful dialogues and coincided with a celebration of POWREX's
55th company anniversary.
The conference doubled as the formal introduction of Microfluidics technology
to Japan. POWREX is Microfluidics' exclusive distributor for Japanese
pharmaceutical, biotechnology and energy industries.
Dr. Panagiotou will next speak at GlaxoSmithKline Research & Development
department in Stevenage, UK, on September 23, followed by a talk at the Material
Research Society meeting in Boston, MA, to be held from November 30-December